Commentary | Published:

The special case of gene therapy pricing

Nature Biotechnology volume 32, pages 874876 (2014) | Download Citation

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Genet. Eng. News 33, 62 (2013).

  2. 2.

    , & Biol. Blood Marrow Transplant. 19, S64–S69 (2013).

  3. 3.

    , & Ther. Deliv. 3, 835–856 (2012).

  4. 4.

    et al. N. Engl. J. Med. 358, 2240–2248 (2008).

  5. 5.

    et al. N. Engl. J. Med. 365, 2357–2365 (2011).

  6. 6.

    et al. Blood 119, 3038–3041 (2012).

  7. 7.

    et al. Hum. Gene Ther. Clin. Dev. 24, 55–64 (2013).

  8. 8.

    Anonymous. Delivering gene therapy to patients. Presented at the Jefferies 2014 Global Healthcare Conference, June 2–5, 2014, New York.

  9. 9.

    Milbank Q. 89, 450–502 (2011).

  10. 10.

    & Genome Med. 1, 114 (2009).

  11. 11.

    & Health Aff. (Millwood) 24, 653–665 (2005).

  12. 12.

    in Innovation Policy and the Economy (eds. Jaffe, A., Lerner, J. & Stern, S.) (MIT Press, Boston, 2001).

  13. 13.

    National Library of Medicine. Genetics Home Reference (National Library of Medicine, 2014).

  14. 14.

    & J. Am. Med. Assoc. 312, 593–594 (2014).

  15. 15.

    Hartfordbusiness.com, vol. 2014 Cigna, Merck ink pay-for-performance deal. (The Hartford Business Journal, 2009). <>

  16. 16.

    , , & Law and the Health System: Casebook Series (Foundation Press, 2014).

Download references

Author information

Affiliations

  1. Troyen A. Brennan is at CVS Caremark, Woonsocket, Rhode Island, USA.

    • Troyen A Brennan
  2. James M. Wilson is at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • James M Wilson

Authors

  1. Search for Troyen A Brennan in:

  2. Search for James M Wilson in:

Competing interests

J.M.W. is an advisor to and a founder of ReGenX Biosciences and Dimension Therapeutics; he also holds equity in and receives a grant from these companies. In addition, he is an inventor on patents licensed to various biopharmaceutical companies, including affiliates of ReGenX Holdings, and consults on an ad hoc basis for several biopharmaceutical companies. He is an inventor on the vector used in the Glybera product. T.A.B. is employed by and holds stock in CVS Caremark.

Corresponding author

Correspondence to Troyen A Brennan.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.3003

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing